Genrix Bio

aka Genrix (Shanghai) Biopharmaceutical, 智翔金泰, SSE:688443

Genrix Bio is a Shanghai antibody company, listed on the Shanghai STAR market, whose oncology lead GR1803 is a BCMA and CD3 bispecific T-cell engager for multiple myeloma.

Genrix (Shanghai) Biopharmaceutical, a subsidiary of Zhifei Biological Products, develops monoclonal and bispecific antibodies. Its first approved product is the IL-17A antibody xeligekimab for psoriasis; its pipeline spans autoimmune, infectious and cancer indications. GR1803, a bispecific antibody binding BCMA on myeloma cells and CD3 on T cells, is in a phase 1/2 trial in relapsed or refractory multiple myeloma.

Headquarters

Shanghai, CN

Scorecard

All companies

#336of 1181 companies, score 10

phase 3 +3
modalities +2
registry trials +5

0 approved, 1 in phase 3, 0 earlier, 0 targets, 7 registry studies. Formula on the scorecards page.

Type

biotech · SSE:688443

Stage

Public

Products

1top

Phase 3bispecific antibody (BCMA x CD3, per the sponsor's pipeline page; form not stated in the registry record)

GR1803

GR1803 is an experimental investigational agent whose form is not stated in the registry from Genrix (Shanghai) Biopharmaceutical in phase 3 trials for multiple myeloma, with its target not yet stated publicly.

Connected